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a b s t r a c t
Introduction: The antiphospholipid syndrome (APS) is an autoimmune condition charac-
terized by recurrent arterial and venous thrombosis, besides obstetric complications. The 
pathogenesis is associated with the presence of antiphospholipid and/or anti-b2-glicopro-
tein I (anti-b2GPI) antibodies that appear to change the anticoagulant activity of b2GPI. 
Antibody-induced dimerization of b2GPI seems to be related to the induction of platelet 
aggregation, contributing to the development of thrombosis in APS.
Objectives: The objective of the present study is to demonstrate the infl uence of antiphos-
pholipid antibodies in platelet aggregation tests with different agonists (ADP, collagen, and 
adrenaline). 
Methods: We analyzed platelet aggregation tests with different agonists (ADP, collagen, 
adrenalin) when normal platelets were exposed to serum with different concentrations of 
antiphospholipid antibodies. 
Results: Results demonstrated a signifi cant inhibition in adrenalin- and ADP-induced plate-
let aggregation curves (P < 0.05) in all antibody concentrations tested when compared to the 
control. The paradox between the prothrombotic state and the presence of autoantibodies 
that show anticoagulant activity in vitro was demonstrated in the literature, making it dif-
fi cult to understand the pathophysiologic mechanism of the antiphospholipid syndrome. 
Conclusion: Results showed that anticardiolipin and anti-b2GPI antibodies-rich serum, both 
of which belonging to the IgG class, can interfere with platelet aggregation curves.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Avaliação da agregação plaquetária em presença de anticorpos 





r e s u m o
Introdução: A síndrome antifosfolípide (SAF) é uma condição autoimune que apresenta fe-
nômenos trombóticos arteriais e venosos de repetição além de complicações obstétricas. 
Sua patogênese está associada à presença de anticorpos antifosfolípides e/ou anti-β2 glico-
proteína I (β2GPI) que aparentemente modifi cam o efeito anticoagulante da β2GPI. A dime-
rização da β2GPI induzida por anticorpos parece estar relacionada à indução da agregação 
plaquetária contribuindo para o estado trombofílico na SAF. 
Objetivos: O presente trabalho objetiva demonstrar a infl uencia dos anticorpos antifosfolí-
pides em testes de agregação plaquetária com diferentes agonistas (ADP, colágeno e adre-
nalina). 
Métodos: Foram analisados testes de agregação de plaquetas normais com diferentes ago-
nistas (ADP, colágeno, adrenalina) na presença de soro contendo anticorpos antifosfolípi-
des em diferentes concentrações. 
Resultados: As análises obtidas mostraram uma inibição signifi cativa (P < 0,05) nas curvas de 
agregação plaquetária induzidas por ADP e adrenalina quando comparadas ao controle. O 
paradoxo entre o estado protrombótico e a presença de autoanticorpos que in vitro apresen-
tam atividade anticoagulante foi demonstrado na literatura, difi cultando o entendimento 
patofi siológico da síndrome antifosfolípide. 
Conclusão: Os resultados obtidos demonstraram que o soro rico em anticorpos anticardio-
lipina e anti-β2GPI, ambas da classe IgG, interferem em testes de curvas de agregação pla-
quetária.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Primary antiphospholipid syndrome (APS) is a clinical condi-
tion characterized by recurrent venous and arterial thrombo-
sis and fetal mortality with recurrent miscarriage associated 
with the presence of antiphospholipid antibodies (aPL).1,2
Laboratorial tests to characterize APS include immunoas-
say for anticardiolipin (aCL) IgM and IgG antibodies, anti-β2-
glycoprotein-I antibodies, and coagulation tests to determine 
the presence of lupus anticoagulant (LA). Confi rmation of 
the presence of these antibodies 12 weeks after they are fi rst 
identifi ed in the patient’s serum allows the exclusion of tran-
sitory cases and the classifi cation of patients according to the 
criteria of the XI International Congress on antiphospholipid 
antibodies in Sydney, Australia, 2006.3,4,5
β2-glycoprotein-I, also known as apolipoprotein H, is a 
phospholipid cofactor with anticoagulant characteristics. It 
has an important role in the preservation of vascular endo-
thelial surface, forming a complex with phospholipids and 
prothrombin. It inhibits the activation of coagulation factor 
XII and it seems to contribute with the activation of protein 
C. On platelet surfaces, β2GPI inhibits the generation of factor 
Xa, besides blocking platelet aggregation and conversion of 
prothrombin to thrombin.6
The pathogenesis of APS is uncertain, but it is believed 
that the interaction of autoantibodies against anionic phos-
pholipids or against β2GPI present on platelets would be 
associated with the release of thrombogenic components. 
Antiphospholipid antibodies would occupy spaces on the 
β2GPI-prothrombin complex, with the consequent endothe-
lial and platelet activation.7
To understand the pathophysiology of this syndrome, one 
should analyze the different clinical types of APS and the 
elements considered to participate of the pathophysiologi-
cal process of the disease, such as platelets, thrombin, and 
β2GPI. The search for the main reasons of this phenomenon 
will provide better therapeutic choices for these patients in 
the future. Therefore, the study of laboratory tests used in the 
diagnosis of this syndrome is paramount.
Material and methods
Female patient with APS
A female patient with APS, according to the criteria of the 
XI International Congress on antiphospholipid antibodies in 
Sydney, Australia, 2006,3 was selected to obtain the serum 
with aPL. The study was approved by the ethics on research 
committee of the Universidade Santo Amaro with registry 
number 069/2011, and the patient signed an informed con-
sent.
A 24-year old female patient who lived in Volta Redonda, 
RJ, experienced a miscarriage in November 2000, in the 12th 
week of pregnancy, and again in March 2002, in her second 
pregnancy, approximately in the 18th week. The histopatholo-
gy of the second miscarriage showed partial fetal and placen-
tal autolysis due to extensive ischemic infarctions, suggestive 
of deep venous thrombosis of maternal origin. Soon after the 
second miscarriage (May 2002), the patient developed hyper-
tension and episodes of absence that were related to probable 
cerebral ischemia, which made her clinician suspect of pro-
thrombotic and circulatory disorders.
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Table 2 – Results of anti-ȕ2GPI antibodies in samples A1, 





A1 Lower than 5 U/mL Greater than 100 
U/mL
A2 Lower than 5 U/mL Greater than 100 
U/mL
A3 Lower than 5 U/mL Greater than 100 
U/mL
Reference values IgM:
Negative ĺ Lower 
than 5 U/mL
Undetermined ĺ 5-8 
U/mL
Positive ĺ Above 8 
U mL
IgG:




Positive ĺ Above 8 
U/mL






A1 12.3 MPL 71.1 GPL
A2 10.5 MPL 71.9 GPL
A3 10.8 MPL 72.4 GPL
Reference values* IgM:






Strong reactivity ĺ 
Above 80 MPL
IgG:






Strong reactivity ĺ 
Above 80 GPL
*Reference value for EliA IgG/IgM (ImmunoCAP 250, Phadia, 
Pharmacia Diagnostics®).
Laboratory tests requested by her clinician in May 2002 
showed: aPTT 28 sec. with normal values ranging from 25-
35 sec., and INR 1.0; antinuclear factor (ANF) and rheumatoid 
factor non reactive; positive VDRL titers 1:4; FTA-ABS IgM and 
IgG negative; positive direct Coombs; IgG aCL antibodies 65 
GPL (negative < 10 GPL); IgM aCL antibodies 15 MPL (normal 
< 10 MPL). Complete blood count showed 6,500 leukocytes/
mm3 (normal = 4,500-11,000) without left shift; mild anemia 
with hematocrit of 35% (normal = 37-47%); hemoglobin 11.8 
g/dL (normal = 12-16 g/dL); RBC = 3.5 million/mm3 (normal = 
4-5.5 million/mm3), and mild thrombocytopenia, with 135,000 
platelets/mm3 (normal = 150,00-400,000/mm3). Biochemistry 
showed normal glucose and liver function tests (AST, ALT, and 
bilirubin), but the patient had mild change in creatinine clear-
ance, at 85 mL/min (normal = 97-130 mL/min).
Anticardiolipin antibodies were positive two other times 
in routine tests, in September 2002 (IgG aCL 73 GPL and IgM 
aCL 13.5 MPL) and October 2002 (IgG aCL 63 GPL and IgM aCL 
11.5 MPL). Positive aCL at intervals greater than 12 weeks 
(May, September, and October), associated with clinical crite-
ria of recurrent miscarriages allowed her characterization as 
having primary antiphospholipid syndrome, according to the 
criteria established in Sydney, in 2006.3 Treatment with anti-
coagulants was instituted with periodic PT and INR.
aPL antibodies
During three months, one blood sample a month was collected 
from the patient in a tube without anticoagulant. Blood sam-
ples were centrifuged at 3,000 rotations per minute (rpms) for 
10 minutes, and the serum was labeled sample 1 (A1), sample 
2 (A2), and sample 3 (A3), as it was collected. Since the patient 
was on oral anticoagulant, under close supervision of her cli-
nician and strict evaluation of possible risks, those medica-
tions were discontinued 7 days prior to the collection date to 
avoid interference with the procedure.8
Lupus anticoagulant testing, performed through the Russell 
viper venom test (Dade Behring®) was negative (integrated au-
tomated test which includes the screening and confi rmation 
testing) and confi rmed by aPTT testing with silica activator.9
Quantifi cation of aPL for aCL and anti-β2GPI antibodies was 
done using the IgG/IgM EliA immunoassay (ImmunoCAP 250, 
Phadia, Pharmacia Diagnostics®), with sensitivity and speci-
fi city similar to other immunoassay testing, such as ELISA, for 
antiphospholipid antibodies.10 Results were reported in IgG 
phospholipid units (GPL) and IgM phospholipid units (MPL) 
where 1 unit is equal to 1 mg/mL of IgG or IgM (Tables 1 and 2).
Platelet aggregation test
The pool of platelet-rich plasma (PRP) was obtained from 20 
healthy volunteers, ages 28-43 years, without a history of co-
agulation disorders, and with normal PT and aPTT. After the 
pool was obtained, it underwent aPL testing (IgM and IgG an-
ticardiolipin antibodies and IgM and IgG anti-β2GPI antibod-
ies), using the same method used in the aPL-rich serum, with 
negative results (less than 10 MPL, for IgM aCL, and less than 
10 GPL, for IgG aCL). Blood samples were collected in tubes 
with sodium citrate at a rate of 1:9 and centrifuged at 1,000 
rpm for 15 minutes. The pool of plasma obtained was used as 
control for aggregation curves. Platelet-poor plasma (PPP) was 
obtained from these patients for calibration of the aggregom-
eter after centrifugation at 2,500 rpm for 10 minutes. Agonists 
used included: ADP (1 μL-1nM), collagen (0,5 μL-1 mg/mL), and 
adrenaline (0,5 μL-1 mg/mL) (Chrono-par®, Chrono-log Cor-
poration, USA) and platelet aggregation tests were performed 
in a Chrono-log aggregometer model 530 (Biomédica S/C Ltda).
aPL-containing serum samples, A1, A2, and A3, were added 
to the PRP with a fi nal volume of 500 μL (Table 3) and un-
derwent aggregation. The number of platelets in the samples 
was verifi ed and standardized in 300,000/mm3 in all samples, 
an adequate number for the aggregation tests performed in 
the equipment used.11 The Mann-Whitney test was used to 
analyze the results, adopting a signifi cance level of P < 0.05.
Results
Tables 4, 5, and 6 show the mean and standard deviation (M ± 
SD) of the results of platelet aggregation expressed in % after 
5 minutes using the pool of control PRP and after the addition 
of the aPL in different concentrations, A1, A2, and A3.
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Table 3 – Volume of addition of samples A1, A2, and A3 






concentration of the 
aggregant added
A1/A2/A3 50 μL 450 μL ADP (1 μL – 1 nM)
A1/A2/A3 100 μL 400 μL ADP (1 μL – 1 nM)
A1/A2/A3 150 μL 350 μL ADP (1 μL – 1 nM)
A1/A2/A3 50 μL 450 μL Colagen 
(0.5 μL – 1 mg/mL)
A1/A2/A3 100 μL 400 μL Colagen 
(0.5 μL – 1 mg/mL)
A1/A2/A3 150 μL 350 μL Colagen 
(0.5 μL – 1 mg/mL)
A1/A2/A3 50 μL 450 Adrenaline (1 μL – 5 nM)
A1/A2/A3 100 μL 400 Adrenaline (1 μL – 5 nM)
A1/A2/A3 150 μL 350 Adrenaline (1 μL – 5 nM)
Table 4 – Mean aggregation % of samples A1, A2, and A3 
after 5 minutes of aggregation with adrenaline.
Control 50 μL 100 μL 150 μL
A1 = 70% A1 = 59% A1 = 56% A1 = 53%
A2 = 70% A2 = 61% A2 = 60% A2 = 57%
A3 = 70% A3 = 56 % A3 = 52% A3 = 50%
Mean = 70% Mean = 59% Mean = 56% Mean = 53%
P = 0.016 P = 0.026 P = 0.014
According to the Mann-Whitney test, a signifi cant inhibition (P < 0.05) 
was observed in samples A1, A2, and A3 for the agonist adrenaline.
Table 5 – Mean aggregation % of samples A1, A2, and A3 
after 5 minutes of aggregation with ADP.
Control 50 μL 100 μL 150 μL
A1 = 74% A1 = 74% A1 = 59% A1 = 58%
A2 = 74% A2 = 58% A2 = 63% A2 = 56%
A3 = 74% A3 = 58% A3 = 58% A3 = 51%
Mean = 74% Mean = 63% Mean = 60% Mean = 55%
P = 0.184 P = 0.012 P = 0.012
According to the Mann-Whitney test, a signifi cant inhibition 
(P < 0.05) was observed for samples A1, A2, and A3 for the agonist 
ADP in the volumes of 100 μL and 150 μL.
Table 6 – Mean aggregation % of samples A1, A2, and A3 
after 5 minutes of aggregation with collagen.
Control 50 μL 100 μL 150 μL
A1 = 70% A1 = 69% A1 = 69% A1 = 68%
A2 = 67% A2 = 65% A2 = 63% A2 = 62%
A3 = 67% A3 = 65% A3 = 60% A3 = 53%
Mean = 68% Mean = 66% Mean = 64% Mean = 61%
P = 0.378 P = 0.267 P = 0.246
According to the Mann-Whitney, test, signifi cant inhibition was 
not observed (P > 0.05) for samples A1, A2, and A3 for the agonist 
collagen.
Table 4, for the aggregant adrenaline, shows a statistically 
signifi cant fall (P < 0.05) in the values of platelet aggregation 
in the presence of anti-β2GPI IgG- and aCL IgG-rich serum.
Regarding the agonist ADP, shown in Table 5, a statistically 
signifi cant fall was also observed with the two higher concen-
trations of anti-β2GPI IgG and aCL IgG (P < 0.05).
As for the agonist collagen, whose values are shown in 
table 6, a statistically signifi cant infl uence was not observed 
with anti-β2GPI IgG and aCL IgG (P > 0.05).
Discussion
The characteristic of APS is the association of several clinical 
aspects, including arterial or venous thrombosis and morbid-
ity during pregnancy (recurring fetal loss, preeclampsia, ec-
lampsia, and spontaneous miscarriages) associated with the 
presence of aPL.12
The name APS seems to be incorrect due to the discovery 
that some forms of aPL are not directed against phospholip-
ids, but against proteins with phospholipid complexes, such 
as β2GPI, prothrombin, and annexin V.
5,13-15 Prior studies sug-
gest that anti-β2GPI in complexes with β2GPI activates plate-
lets, potentially contributing for the thrombotic tendency of 
patients with APS. However, the presence of aPL does not im-
plicates in the development of APS, as they can be present 
in up to 1% of the normal population and in 3% of elderly 
individuals.16-18
To verify whether evidence of in vivo platelet hyperac-
tivity would be reproduced in vitro, analysis of platelet ag-
gregation curves with different agonists in the presence of 
aPL-rich human serum of a patient with primary APS diag-
nosed according to the criteria of the XI International Con-
gress on antiphospholipid antibodies held in Sydney, in 2006, 
was performed. Samples collected from the patient at vary-
ing intervals showed elevated IgG aCL, which the literature 
has indicated to be more relevant than the IgM aCL regarding 
thrombotic phenomena.19 The titers of anti-β2GPI IgG antibod-
ies were also elevated in all three samples (> 100 U/mL). These 
antibodies are fundamental for the clinical aspects of APS, 
since the β2GPI plasma protein to which they bind has a great 
affi nity for anionic phospholipids, working as a cofactor for 
the development of APS.20
The results showed a statistically signifi cant (P < 0.05) in-
hibition of platelet aggregation for adrenaline, in all antibody 
concentrations, and ADP, in the two highest antibody concen-
trations. As for collagen, the inhibition was non-signifi cant.
This apparent paradox between aPL and the inhibition of 
platelet aggregation was also demonstrated in a recent study 
in which elevated levels of anti-β2GPI antibodies reduced sig-
nifi cantly platelet aggregation (this inhibition was propor-
tional to the concentration of said antibodies) in the presence 
of the aggregants, ADP and collagen.21
The inhibition of platelet aggregation after addition of aCL- 
and anti-β2GPI antibodies-containing serum in vitro suggests 
that other factors are implied in the thrombotic phenomena 
that occur in vivo. Activation of endothelial cells, endothe-
lial lesion mediated by oxidants, interference with proteins 
that bind anionic phospholipids responsible for hemostasis, 
interactions of these antibodies with monocytes or natural 
anticoagulants, such as proteins S and C, can also justify the 
vaso-occlusive phenomena.22 Another possibility would be 
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that anti-β2GPI antibodies may inhibit the release of platelet 
dense granules and inhibit the arachidonic acid metabolic 
pathway.21
In a selection of clinical studies performed with aPL, only 
LA was consistently related as a risk factor for clinical throm-
botic phenomena. However, studies with aCL and anti-β2GPI 
antibodies were inconclusive and partly controversial. aCL 
IgG and anti-β2GPI IgG demonstrated greater relationship 
with thrombotic processes (aCL related to more specifi c situ-
ations of stroke and myocardial lesions) than the respective 
IgM antibodies, but they did not show the close relationship 
that LA has with those phenomena.23
The aforementioned data seem important for the interpre-
tation of our results of inhibition of platelet aggregation, since 
the level of LA of the patient with primary APS was negative 
in the samples used for the testing, and these antibodies are 
more closely related to clinical thrombosis.
Besides, other authors have demonstrated, in patients 
with thromboembolic complications, the presence of autoan-
tibodies that, in vitro, showed to have anticoagulant activity 
and caused prolongation of coagulation tests.20
The results of the present study suggest that the in vivo 
thrombotic effect of aPL can be associated to the type of anti-
bodies present in the patient with APS and other factors that 
were not detected in the in vitro aggregation test. The use of 
these aggregation tests for diagnosis can cause misinterpre-
tation and failure to refer the patient to test for the presence 
of aPL even in the presence of symptomatology compatible 
with APS.
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